Transaction · 0002163153-26-000002

Pussinen Cynthia

Pussinen Cynthia, CEO, reported a transaction classified as grant at Estrella Immunopharma, Inc. involving 1000000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 1000000.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACEO
ESLAEstrella Immunopharma, Inc.
Trade date
Nov 02, 2026
Filing date
Nov 04, 2026
View on SEC Insider profile
Disclosed value$0Shares × reported price
Shares traded1.00M$0.00 per share
Holdings after1.00MDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

ESLA price since this filing

Daily closing prices, with the filing date and available return windows
ESLA · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -42.7%1w ago +12.2%1d ago +0.0%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0002163153-26-000002
Stock Option (Right to Buy)
Transaction date
Nov 02, 2026
Filed Nov 04, 2026, 12:23 PM · 2d delay
Shares
1,000,000 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
1,000,000 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Increase
Filing-only score

-6 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Executive Officer

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The option vests and becomes exercisable as to 25% of the underlying shares on October 25, 2027 and as to the remaining 75% in 36 substantially equal monthly installments thereafter, subject to the re…

  2. F2

    The option was granted under the Issuer's 2023 Omnibus Incentive Plan and was approved in advance by the Compensation Committee of the Board of Directors and the Board of Directors in accordance with…

Original filing · 0002163153-26-000002
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ESLA